Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815306 | 0.85 | EPHX2 (0.43) | EPHX2HCRTR1HCRTR2SMN1; SMN2TRPV1 | |
| SCHEMBL14815174 | 0.84 | EPHX2 (0.44) | EPHX2HCRTR1HCRTR2TRPV1CCR6 | |
| SCHEMBL14815213 | 0.82 | HCRTR2 (0.41) | EPHX2HCRTR1HCRTR2LMNA | |
| SCHEMBL14815468 | 0.82 | EPHX2 (0.46) | EPHX2HCRTR1HCRTR2TRPV1DPP4 | |
| SCHEMBL14815549 | 0.80 | EPHX2 (0.41) | EPHX2HCRTR1HCRTR2TRPV1CCR6 | |
| SCHEMBL14815455 | 0.79 | MGLL (0.49) | HCRTR1HCRTR2GAA | |
| SCHEMBL14814665 | 0.75 | EPHX2 (0.51) | EPHX2HCRTR1HCRTR2SMN1; SMN2HPGD | |
| SCHEMBL14833487 | 0.75 | EPHX2 (0.51) | EPHX2HCRTR1HCRTR2SMN1; SMN2HPGD | |
| SCHEMBL14814682 | 0.72 | HCRTR1 (0.40) | HCRTR1HCRTR2CCR6 | |
| SCHEMBL14815442 | 0.71 | MGLL (0.52) | SMN1; SMN2HPGDPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | EPHX2 2168/4885HCRTR1 654/4885HCRTR2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.